L. Yin

ORCID: 0000-0003-1112-583X
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Lymphoma Diagnosis and Treatment
  • Water-Energy-Food Nexus Studies
  • Brain Metastases and Treatment
  • Lung Cancer Treatments and Mutations
  • Lung Cancer Research Studies
  • Viral-associated cancers and disorders
  • Microscopic Colitis
  • Inflammatory Bowel Disease
  • Advanced Drug Delivery Systems
  • Water Resources and Sustainability
  • Vascular Tumors and Angiosarcomas

Northeast Agricultural University
2025

Jiangsu Hengrui Medicine (China)
2023

Hangzhou Medical College
2023

Qinghai University Affiliated Hospital
2021

Abstract Conventional oral therapy for ulcerative colitis (UC) is associated with premature release or degradation of drugs in the harsh gastrointestinal environment, resulting reduced therapeutic effectiveness. Consequently, present study aims to develop a dual‐targeted delivery system nanoparticle‐in‐microparticle (nano‐in‐micro) structure. The prepared Asiatic Acid‐loaded (AA/CDM‐BT‐ALG) has pH‐sensitive properties. Cellular uptake evaluation confirms that nanoparticles exhibit targeted...

10.1002/adhm.202301518 article EN Advanced Healthcare Materials 2023-09-03

Previous studies on carrying capacity have primarily focused measuring agricultural production conditions while neglecting the coupling effects among conditions, materials, and external environment (the of water, soil, energy, environment). Therefore, this paper introduces concept a regional water–land–energy system (WLECS); develops an evaluation framework comprising 27 indicators from perspectives stability, collaboration, resilience constructs improved random forest model based red-billed...

10.3390/su17041669 article EN Sustainability 2025-02-17

This study evaluated the survival benefit of asparaginase (ASP)-based versus non-ASP-based chemotherapy combined with radiotherapy in a real-world cohort patients early-stage extranodal nasal-type natural killer/T-cell lymphoma (ENKTCL).We identified 376 who received either ASP-based (ASP, platinum, and gemcitabine; n = 286) or (platinum 90) regimens. The were stratified into low-, intermediate-, high-risk groups using early stage-adjusted nomogram-revised risk index. Overall (OS) distant...

10.1016/j.esmoop.2021.100206 article EN cc-by-nc-nd ESMO Open 2021-07-07
Coming Soon ...